“Sustained Improvement in Patient-Reported Outcomes With Continued Apremilast Treatment over 104 Weeks in Patients With Moderate to Severe Psoriasis”. 2018. SKIN The Journal of Cutaneous Medicine 2 (S1): S23. https://doi.org/10.25251/skin.2.supp.23.